Evidence map›Paper›PMID 41630040›Full record

ArticleTrials2026

Suvorexant for alcohol use disorder and post-traumatic stress disorder: study protocol for a phase II randomized clinical trial.

Lara A Ray, Steven J Nieto, Karen Miotto, Larissa Mooney, Richard LeBeau, Jin H Yoon, Joy M Schmitz, Ron Acierno, Nathaniel W Bailey, Jessica Jenkins and 5 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06679062 (A Double-masked, Randomized, Phase II Study to Compare the Effectiveness of 20mg Oral Suvorexant), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06679062 phase2recruitingnot on this map

A Double-masked, Randomized, Phase II Study to Compare the Effectiveness of 20mg Oral Suvorexant (SUV) Versus Placebo (1:1) in Participants With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)

TypeinterventionalSponsorPharmacotherapies for Alcohol and Substance Use Disorders AllianceRan2025 to 2027Enrolled76ConditionsAlcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD), InsomniaArmsSuvorexant, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lara A RayDepartment of Psychology, University of California at Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA. lararay@psych.ucla.edu.ORCID http://orcid.org/0000-0002-5734-9444
Steven J NietoDepartment of Psychology, University of California at Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
Karen MiottoDepartment of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, CA, USA.
Larissa MooneyDepartment of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, CA, USA.
Richard LeBeauDepartment of Psychology, University of California at Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
Jin H YoonCenter for Neurobehavioral Research on Addictions, University of Texas Health Science Center-Houston, Houston, TX, USA.
Joy M SchmitzCenter for Neurobehavioral Research on Addictions, University of Texas Health Science Center-Houston, Houston, TX, USA.
Ron AciernoCenter for Neurobehavioral Research on Addictions, University of Texas Health Science Center-Houston, Houston, TX, USA.
Nathaniel W BaileyGlobal Scientific Affairs, Merck & Co., Inc., Rahway, NJ, USA.
Jessica JenkinsDepartment of Psychology, University of California at Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
Jessica VincentCenter for Neurobehavioral Research on Addictions, University of Texas Health Science Center-Houston, Houston, TX, USA.
Tracy NolenSocial, Statistical, & Environmental Sciences, RTI International, Research Triangle Park, Durham, NC, USA.
Shawn HirschSocial, Statistical, & Environmental Sciences, RTI International, Research Triangle Park, Durham, NC, USA.
Alexis WilliamsSocial, Statistical, & Environmental Sciences, RTI International, Research Triangle Park, Durham, NC, USA.
Scott D LaneCenter for Neurobehavioral Research on Addictions, University of Texas Health Science Center-Houston, Houston, TX, USA.

Funding

Congressionally Directed Medical Research Programs W81XWH-22-2-0081
6 · The paper itself

Abstract

backgroundAlcohol use disorder (AUD) represents a highly prevalent, costly, and often untreated condition in the United States. Post-traumatic stress disorder (PTSD) represents a common comorbidity with AUD which worsens outcomes and decreases functional outcomes. Suvorexant (SUV) shows clear promise as a novel therapeutic candidate to treat AUD and PTSD.

methodsThis study features a promising compound (i.e., suvorexant), the application of a well-established human laboratory paradigm (i.e., alcohol cue reactivity), and a novel early efficacy laboratory model (i.e., practice quit attempt) to provide a cost/time-efficient evaluation of safety and initial efficacy of suvorexant for AUD with comorbid PTSD. Additionally, by collecting both objective and subjective sleep measures, the study provides an assessment of a putative mechanism through which suvorexant jointly addresses an intervening variable common to both AUD and PTSD. DISCUSSION: The combination of human laboratory modeling and real-world clinical outcomes provides a unique and synergistic set of data that can advance the development of suvorexant and identify its behavioral mechanisms of action. The recruitment of individuals with AUD and PTSD with sleep disturbances and who are intrinsically motivated to quit is a novel approach to screening pharmacotherapies by bridging the gap between experimental studies with non-treatment seekers and clinical trials with treatment-seeking individuals.

trial registrationClinicalTrials.gov NCT06679062 "Suvorexant for Treatment of AUD and PTSD (SUV)." Registered on November 12, 2024.

Indexed as

AlcoholismAzepinesOrexin Receptor AntagonistsStress Disorders, Post-TraumaticTriazolesClinical Trials, Phase II as TopicHumansRandomized Controlled Trials as TopicSleepTreatment OutcomeAzepinesOrexin Receptor AntagonistssuvorexantTriazolesAlcohol use disorderInsomniaMedication developmentPost-traumatic stress disorderSuvorexant

Identifiers

PMID41630040
PMCPMC12958697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.